复发性喉癌的挽救性手术治疗
回顾性分析1999至2016年Memorial Sloan Kettering癌症中心收治的241例复发性喉癌患者,88%为男性,中位年龄67岁,71%为原发声门肿瘤。2年和5年疾病特异性生存率分别为74%和57%。
要点
- 复发性喉癌挽救性手术可获得可接受的肿瘤学结局,2年和5年DSS分别为74%和57%。
- cT4病变接受非手术原发治疗者5年DSS为0%,提示此类患者预后极差。
- 肿瘤部位、神经周围侵犯、切缘和分期是DSS的独立预测因素。
核心结论
- 挽救性手术治疗复发性喉癌可获得可接受的肿瘤学结局。
- 分期、病变部位、神经周围侵犯和切缘与较差的疾病特异性生存相关。
研究设计与样本
- 回顾性队列研究,纳入1999至2016年在Memorial Sloan Kettering(MSK)治疗的241例复发性喉癌患者。
- 分析生存结局,中位年龄67岁,88%为男性,71%为原发声门肿瘤。
主要发现
- 初次治疗时72%患者为早期病变,原发治疗为放疗(68%)、放化疗(29%)和手术(3%)。
- 2年和5年疾病特异性生存率(DSS)分别为74%和57%。
- cT4病变接受非手术原发治疗的患者5年DSS为0%。
- DSS的独立预测因素包括肿瘤部位、神经周围侵犯、切缘和分期。
临床怎么用
- 对复发性喉癌患者,挽救性手术是可行的治疗选择,但需根据分期、部位、神经周围侵犯和切缘评估预后。
- cT4病变接受非手术原发治疗者挽救性手术预后极差,临床决策需综合考虑。
局限性
- 回顾性研究,可能存在选择偏倚。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite advances in treatment, the recurrence rates for laryngeal cancer range from 16% to 40%. METHODS: Patients with recurrent laryngeal cancer treated at Memorial Sloan Kettering (MSK) from 1999 to 2016 were reviewed. Survival outcomes were analyzed. RESULTS: Of 241 patients, 88% were male; the median age was 67 years; 71% had primary glottic tumors. At initial treatment, 72% of patients were seen with early stage disease; primary treatment was radiation (68%), chemoradiation (29%), and surgery (3%). The most common salvage surgery was total laryngectomy (74%). Forty-seven percentage were upstaged at salvage surgery. The 2- and 5-year disease-specific survival (DSS) was 74% and 57%, respectively. Patients with cT4 disease treated with nonsurgical primary management had a 0% 5-year DSS. Independent predictors of DSS were tumor location, perineural invasion, margin, and stage. CONCLUSIONS: Salvage surgery results in acceptable oncologic outcomes. Stage, disease site, perineural invasion, and margins are associated with inferior DSS.
引用
- Mimica X, Hanson M, Patel SG, et al. Salvage surgery for recurrent larynx cancer. Head Neck. 2019. PMID: 31433540. doi:10.1002/hed.25925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。